- Home
- NRIX vs TRNS Comparison
NRIX vs TRNS Comparison
Compare NRIX & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- TRNS
- Stock Information
- Founded
- NRIX 2009
- TRNS 1964
- Country
- NRIX United States
- TRNS United States
- Employees
- NRIX N/A
- TRNS N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- TRNS Electrical Products
- Sector
- NRIX Health Care
- TRNS Industrials
- Exchange
- NRIX Nasdaq
- TRNS Nasdaq
- Market Cap
- NRIX 766.0M
- TRNS 748.7M
- IPO Year
- NRIX 2020
- TRNS N/A
- Fundamental
- Price
- NRIX $10.56
- TRNS $81.47
- Analyst Decision
- NRIX Strong Buy
- TRNS Buy
- Analyst Count
- NRIX 15
- TRNS 4
- Target Price
- NRIX $29.13
- TRNS $108.67
- AVG Volume (30 Days)
- NRIX 678.5K
- TRNS 81.3K
- Earning Date
- NRIX 10-10-2025
- TRNS 08-06-2025
- Dividend Yield
- NRIX N/A
- TRNS N/A
- EPS Growth
- NRIX N/A
- TRNS N/A
- EPS
- NRIX N/A
- TRNS 1.44
- Revenue
- NRIX $88,381,000.00
- TRNS $288,138,000.00
- Revenue This Year
- NRIX $71.51
- TRNS $10.85
- Revenue Next Year
- NRIX N/A
- TRNS $6.52
- P/E Ratio
- NRIX N/A
- TRNS $59.60
- Revenue Growth
- NRIX 41.86
- TRNS 8.49
- 52 Week Low
- NRIX $8.18
- TRNS $67.56
- 52 Week High
- NRIX $29.56
- TRNS $133.72
- Technical
- Relative Strength Index (RSI)
- NRIX 43.38
- TRNS 50.82
- Support Level
- NRIX $9.44
- TRNS $77.61
- Resistance Level
- NRIX $10.98
- TRNS $86.01
- Average True Range (ATR)
- NRIX 0.57
- TRNS 4.31
- MACD
- NRIX -0.08
- TRNS 0.68
- Stochastic Oscillator
- NRIX 38.75
- TRNS 67.71
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About TRNS Transcat Inc.
Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.